The American College of Rheumatology recently issued new guidelines for rheumatologists to use in their patient treatment decisions about the use on non-biologic and biologic disease modifying anti-rheumatic drugs (DMARDs). The recommendations and guidelines were published in the June issue of the journal, Arthritis Care & Research.
The guidelines are intended to provide guidance to physicians and are voluntary, but are not meant to dictate treatment for every patient, since needs and...

